MedAccess

✨ New milestone for medical oxygen access in East Africa ✨ Earlier this week, MedAccess, Unitaid and the Clinton Health Access Initiative, Inc. announced a new volume guarantee agreement with Synergy Gases (Kenya) Ltd to expand access to affordable liquid medical oxygen across sub-Saharan Africa. This agreement marks a major step forward for the East Africa Program on Oxygen Access (EAPOA), the continent’s first regional initiative to increase the availability of medical oxygen. It’s also the first MedAccess agreement focused specifically on regional manufacturing – an important shift toward building sustainable, locally led health systems. The oxygen will be produced at a new state-of-the-art facility near Kilifi County, Kenya. From there, it will be distributed to hospitals in Kenya, Tanzania and Uganda. The EAPOA aims to expand medical oxygen production by 300% in East Africa. This will: 🚚 Build the foundation for sustainable, local production and distribution. 🫧 Strengthen regional oxygen security so medical oxygen is accessible where – and when – it's needed most. ⬇️ Reduce oxygen prices by up to 27%, saving money for local health authorities and individual hospitals. Find out more about our medical oxygen agreement: https://xmrrwallet.com/cmx.plnkd.in/ecEZVQzw

💥 We aim to act as a catalyst for lasting, systemic change 💥 As each of our innovative finance agreements draws to a close, we evaluate whether our goals have been met and prepare to track sustained impact. This ensures our work continues to deliver value well beyond the lifetime of each agreement. In our latest Annual Review, Head of Impact Tristana Perez shares more about how we track the impact of our agreements throughout their lifecycle - from signing through to the long lasting, ripple effects on markets: 🔗 https://xmrrwallet.com/cmx.plnkd.in/gdrBtrWV

✨ One year ago, Brazil became one of the first malaria-endemic countries to roll out G6PD enzyme testing alongside single-dose tafenoquine – marking a major step forward in the fight to eliminate P. vivax malaria. ✨ Tafenoquine – a ‘radical cure’ treatment – can eliminate the P. vivax malaria parasite from the liver in one dose. But it can also cause severe anaemia in G6PD-deficient patients, which is why G6PD testing is so important. Back in 2022, the G6PD test market was fragile and SD BIOSENSOR INC's G6PD test was the only one on the market. A MedAccess volume guarantee meant SD BIOSENSOR INC's could continue to produce the test and supply it at an affordable price in low- and middle-income countries. Today, more people can access the most effective type of treatment, avoid relapse and live life malaria-free. Find out more about how this life changing test reached some of Brazil’s hardest to reach communities first ⬇️⬇️⬇️

📩 The latest edition of our Access Matters newsletter is out! Inside, we cover: 🔷 A new MedAccess and Synergy Gases (Kenya) Ltd volume guarantee to increase access to medical oxygen - part of the East Africa Programme on Oxygen Access (EAPOA) 🔷 Emilie Grard shares five key takeaways from the 2025 International AIDS Society (IAS) Conference in Kigal 🔷 Kaodili Udeh gives his views on the impact of our medical oxygen agreement 🔷 Mayank Anand joins the Expert Review Committee for the next Access to Medicine Index from the Access to Medicine Foundation Read it here ⬇️

⭐ 2024 was a year of progress at MedAccess ⭐   Highlights include:   💊 Supporting access to products that ensured nearly 18,000 additional people got malaria treatment, 29,500 were successfully treated for drug-resistant TB, and 750,000 people were tested for HIV 🦠 Joining the G7 Development Finance Institutions initiative for better preparedness for future pandemics 👋 Welcoming four new board members with deep experience in global health, aid effectiveness and investing ❤️ Collaborating with country and industry partners throughout the year on new agreements for cancer and nutrition, which we announced in early 2025.    Read more in our 2024 Annual Review: https://xmrrwallet.com/cmx.plnkd.in/gdrBtrWV  

Last week, MedAccess Health Investment Analyst Emilie Grard attended the 2025 International AIDS Society (IAS) Conference in Kigali. The conference brought together global leaders, researchers and advocates to address the rapidly shifting landscape in HIV prevention and care. Discussions focused on how to: 💡 Accelerate access to new innovations 🔬 Sustain momentum on scientific research 🌟 Protect existing programmatic gains. Find out Emilie’s five key takeaways from the conference in our latest Insight article. 🔗 https://xmrrwallet.com/cmx.plnkd.in/e9WJTckT #AIDS2026

📩 Sign up to our monthly Access Matters newsletter and stay up-to-date with the latest news from MedAccess including: ❤️ How our agreements and partnerships are helping patients ✨ Career opportunities, expressions of interest and publications 💡 Insights on market shaping and innovative finance for global health Sign up here: https://xmrrwallet.com/cmx.plnkd.in/eJmSbWmh #HealthForAll | #GlobalHealth | #InnovativeFinance

📣 NEW VOLUME GUARANTEE AGREEMENT 📣 Today MedAccess, Unitaid and the Clinton Health Access Initiative, Inc. announced a new volume guarantee agreement between MedAccess and Synergy Gases (Kenya) Ltd to expand access to affordable liquid oxygen for medical use across sub-Saharan Africa. This agreement marks a major step forward for the East Africa Program on Oxygen Access, the continent’s first regional initiative to increase the availability of medical oxygen. Oxygen is a lifesaving, essential medicine that is critical for treating: 🦠 Pneumonia 😷 COVID-19 💊 Advanced HIV 🦟 Severe tuberculosis and malaria 👶 As well as supporting maternal care, surgery, and emergency treatment. Find out more about the agreement here: https://xmrrwallet.com/cmx.plnkd.in/ecEZVQzw #HealthForAll | #InnovativeFinance

Tuberculosis (TB) is one of the world's most deadly infectious diseases. Meanwhile, drug-resistant TB is a growing crisis – historically, treatment options have been long and complex with toxic side effects. In 2022, the World Health Organization recommended a new regimen – BPaLM – that’s simpler and over 89% effective. However, it includes newer, more expensive drugs. We partnered with Viatris and TB Alliance to reduce the price of pretomanid – the ‘Pa’ in BPaLM. This has resulted in: 🌟29,500 additional patients treated ❌25,300 severe adverse side effects avoided 📉34% price reduction Read more about this partnership and the impact of our innovative finance agreements in our latest Annual Review: https://xmrrwallet.com/cmx.plnkd.in/etZb2cuW

Read the Clinton Health Access Initiative, Inc.'s latest HIV Market Impact Memo, which reveals the human impact of funding cuts to HIV programs. Drawing on data from 13 low- and middle-income countries, the analysis warns that millions more people could face preventable illness and death if urgent action is not taken. Read the full memo here: https://xmrrwallet.com/cmx.plnkd.in/ekmnh2pT #HealthForAll